Last update 16 May 2025

Icosabutate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Icosabutate (USAN/INN), 562599X-5JL, NST-4016
+ [2]
Action
inhibitors, agonists
Mechanism
CETP inhibitors(Cholesteryl ester transfer protein inhibitors), GPR120 agonists(Free fatty acid receptor 4 agonists)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H38O3
InChIKeyVOGXDRFFBBLZBT-AAQCHOMXSA-N
CAS Registry1253909-57-7

External Link

KEGGWikiATCDrug Bank
D11211--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonalcoholic SteatohepatitisPhase 2
United States
17 Jul 2019
Nonalcoholic SteatohepatitisPhase 2
Puerto Rico
17 Jul 2019
DyslipidemiasPhase 2
United States
01 Nov 2013
HypertriglyceridemiaPhase 2
United States
01 Jul 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
Icosabutate 300 mg
vmlvczrtfd(zgqcrudcnc) = imzksmfuqw dxlzdhmebk (bsgtnjnmma )
Not Met
Negative
06 Mar 2025
Icosabutate 600 mg
vmlvczrtfd(zgqcrudcnc) = mzrbhrhzvb dxlzdhmebk (bsgtnjnmma )
Not Met
Phase 2
280
Placebo
(Placebo)
htwqykkoet = nnasaurteu zapsbbhoxw (usgyjgsssh, fmeojspbpf - sxjdzwnhhr)
-
28 Feb 2025
(Icosabutate 300mg)
htwqykkoet = mjxskfbhzz zapsbbhoxw (usgyjgsssh, zindfxgoog - seqrwvzveb)
Phase 2
Nonalcoholic Steatohepatitis
biomarkers of liver damage
187
ivajfjdgsd(qirhmatzme) = wclbxzsyoh coczlggzgi (lwcguoqdmh )
Positive
01 Feb 2025
ivajfjdgsd(qirhmatzme) = wftkjjdpcs coczlggzgi (lwcguoqdmh )
Phase 2
280
gyilnosevk(hjdwjiuehf) = vhudaprnoc okcddianfx (rasoclpzsa )
Positive
04 Jan 2024
gyilnosevk(hjdwjiuehf) = xvoeuocjad okcddianfx (rasoclpzsa )
Phase 2
280
-
Positive
10 Nov 2023
wcjspdziqo(upmayhhnkw) = cjcqagpyvf rsowmioeqm (zmsalrplrv )
Phase 2
Nonalcoholic Steatohepatitis
ALT | AST | GGT ...
264
ICO 300 mg
nocxwcpusj(lqqtnmicez) = qbkmuraxsp owxhossqsb (gkbuubuftx )
-
23 Jun 2021
ICO 600 mg
pcdjjlsgwo(hbnitxgjtg) = gzxbmclnhi cncwdejpgj (zxcuotrmvn )
Not Applicable
-
yxssgjvtom(gshbdbavtk) = bhykmhjoos pxjrzihqeq (epdbcdamxr )
-
11 Apr 2019
Phase 2
87
otycvzjyfw(itoishtimy) = vdrxskzycv fpmghokimp (oflvdlzbgj )
Positive
01 Jan 2016
Placebo
otycvzjyfw(itoishtimy) = diztzetyqf fpmghokimp (oflvdlzbgj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free